ELECTROMEDICAL TECHNOLOGIES, INC. (EMED) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
14/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseEMED / S&P -50.00% / 15.20% |
LoseEMED / S&P EMED unavailable / 15.00% |
LoseEMED / S&P EMED unavailable / 50.40% |
| 2026-Q11/3 |
WinEMED / S&P 0.00% / -4.33% |
LoseEMED / S&P EMED unavailable / 11.30% |
LoseEMED / S&P EMED unavailable / 27.70% |
| 2025-Q40/3 |
LoseEMED / S&P 0.00% / 2.65% |
LoseEMED / S&P EMED unavailable / 9.00% |
LoseEMED / S&P EMED unavailable / 13.40% |
| 2025-Q31/3 |
WinEMED / S&P 100.00% / 8.12% |
LoseEMED / S&P EMED unavailable / 4.61% |
LoseEMED / S&P EMED unavailable / 13.45% |
| 2025-Q20/3 |
LoseEMED / S&P -50.00% / 10.94% |
LoseEMED / S&P EMED unavailable / 4.83% |
LoseEMED / S&P EMED unavailable / 10.63% |
| 2025-Q10/3 |
LoseEMED / S&P -50.00% / -4.27% |
LoseEMED / S&P EMED unavailable / 4.98% |
LoseEMED / S&P EMED unavailable / 10.57% |
| 2024-Q40/3 |
LoseEMED / S&P -20.00% / 2.41% |
LoseEMED / S&P EMED unavailable / 5.25% |
LoseEMED / S&P EMED unavailable / 6.15% |
| 2024-Q30/3 |
LoseEMED / S&P -9.09% / 5.89% |
LoseEMED / S&P -35.09% / 5.89% |
LoseEMED / S&P EMED unavailable / 6.11% |
| 2024-Q20/3 |
LoseEMED / S&P -35.29% / 4.28% |
LoseEMED / S&P -12.58% / 5.38% |
LoseEMED / S&P -136.36% / 5.12% |
| 2024-Q11/3 |
WinEMED / S&P 21.43% / 10.56% |
LoseEMED / S&P -3.54% / 5.71% |
LoseEMED / S&P -136.36% / 5.59% |
| 2023-Q41/3 |
LoseEMED / S&P 0.00% / 11.69% |
WinEMED / S&P 17.30% / 6.81% |
LoseEMED / S&P -126.67% / 7.78% |
| 2023-Q31/3 |
LoseEMED / S&P -12.50% / -3.27% |
WinEMED / S&P 47.42% / 7.52% |
LoseEMED / S&P -69175290276410912.00% / -5.03% |
| 2023-Q21/3 |
LoseEMED / S&P -84.00% / 8.74% |
WinEMED / S&P 39.71% / 9.50% |
LoseEMED / S&P -56.00% / -8.57% |
| 2023-Q11/3 |
LoseEMED / S&P -25.37% / 7.50% |
WinEMED / S&P 35.71% / 10.77% |
LoseEMED / S&P -86.25% / -15.69% |
| 2022-Q41/3 |
LoseEMED / S&P -34.95% / 7.56% |
WinEMED / S&P 26.72% / 11.88% |
LoseEMED / S&P -88.46% / -17.99% |
| 2022-Q30/3 |
LoseEMED / S&P -33.97% / -4.88% |
LoseEMED / S&P 13.22% / 13.47% |
LoseEMED / S&P EMED unavailable / -1.41% |
| 2022-Q21/3 |
LoseEMED / S&P -61.48% / -16.10% |
WinEMED / S&P 30.35% / 13.71% |
LoseEMED / S&P EMED unavailable / 11.04% |
| 2022-Q11/3 |
LoseEMED / S&P -39.14% / -4.60% |
WinEMED / S&P 39.63% / 15.97% |
LoseEMED / S&P EMED unavailable / 42.23% |
| 2021-Q41/3 |
LoseEMED / S&P -48.37% / 11.03% |
WinEMED / S&P 22.96% / 15.00% |
LoseEMED / S&P EMED unavailable / 96.40% |
| 2021-Q32/3 |
WinEMED / S&P 76.58% / 0.58% |
WinEMED / S&P 11.66% / 10.77% |
LoseEMED / S&P EMED unavailable / 69.42% |
| 2021-Q20/3 |
LoseEMED / S&P -67.56% / 8.55% |
LoseEMED / S&P -8.56% / 6.58% |
LoseEMED / S&P EMED unavailable / 51.81% |
| 2021-Q10/3 |
LoseEMED / S&P -25.00% / 6.17% |
LoseEMED / S&P EMED unavailable / -1.06% |
LoseEMED / S&P EMED unavailable / 7.39% |
| 2020-Q40/3 |
LoseEMED / S&P -56.27% / 12.15% |
LoseEMED / S&P EMED unavailable / -3.72% |
LoseEMED / S&P EMED unavailable / -33.42% |
| 2020-Q30/3 |
LoseEMED / S&P -39.82% / 8.93% |
LoseEMED / S&P EMED unavailable / -2.04% |
LoseEMED / S&P EMED unavailable / -27.10% |
| 2020-Q21/3 |
WinEMED / S&P 279.87% / 20.54% |
LoseEMED / S&P EMED unavailable / -0.46% |
LoseEMED / S&P EMED unavailable / -27.11% |
| 2020-Q10/3 |
LoseEMED / S&P -85.36% / -19.60% |
LoseEMED / S&P EMED unavailable / 3.47% |
LoseEMED / S&P EMED unavailable / -14.75% |
| 2019-Q40/3 |
LoseEMED / S&P 5.67% / 9.07% |
LoseEMED / S&P EMED unavailable / 5.36% |
LoseEMED / S&P EMED unavailable / 2.99% |
| 2019-Q30/3 |
LoseEMED / S&P EMED unavailable / 1.70% |
LoseEMED / S&P EMED unavailable / 5.02% |
LoseEMED / S&P EMED unavailable / 0.21% |
| 2019-Q20/3 |
LoseEMED / S&P EMED unavailable / 4.30% |
LoseEMED / S&P EMED unavailable / 6.64% |
LoseEMED / S&P EMED unavailable / 8.65% |
| 2019-Q10/3 |
LoseEMED / S&P EMED unavailable / 13.65% |
LoseEMED / S&P EMED unavailable / 8.12% |
LoseEMED / S&P EMED unavailable / 14.29% |
| 2018-Q40/3 |
LoseEMED / S&P EMED unavailable / -13.52% |
LoseEMED / S&P EMED unavailable / 9.05% |
LoseEMED / S&P EMED unavailable / 18.23% |
| 2018-Q30/3 |
LoseEMED / S&P EMED unavailable / 7.71% |
LoseEMED / S&P EMED unavailable / 10.21% |
LoseEMED / S&P EMED unavailable / 19.06% |
| 2018-Q20/3 |
LoseEMED / S&P EMED unavailable / 3.43% |
LoseEMED / S&P EMED unavailable / 9.03% |
LoseEMED / S&P EMED unavailable / 14.46% |
| 2018-Q10/3 |
LoseEMED / S&P EMED unavailable / -0.76% |
LoseEMED / S&P EMED unavailable / 7.68% |
LoseEMED / S&P EMED unavailable / 12.46% |
| 2017-Q40/3 |
LoseEMED / S&P EMED unavailable / 6.64% |
LoseEMED / S&P EMED unavailable / 7.03% |
LoseEMED / S&P EMED unavailable / 13.82% |
| 2017-Q30/3 |
LoseEMED / S&P EMED unavailable / 4.48% |
LoseEMED / S&P EMED unavailable / 5.68% |
LoseEMED / S&P EMED unavailable / 17.57% |
| 2017-Q20/3 |
LoseEMED / S&P EMED unavailable / 3.09% |
LoseEMED / S&P EMED unavailable / 4.83% |
LoseEMED / S&P EMED unavailable / 17.74% |
| 2017-Q10/3 |
LoseEMED / S&P EMED unavailable / 6.07% |
LoseEMED / S&P EMED unavailable / 3.67% |
LoseEMED / S&P EMED unavailable / 13.32% |
| 2016-Q40/3 |
LoseEMED / S&P EMED unavailable / 3.82% |
LoseEMED / S&P EMED unavailable / 2.09% |
LoseEMED / S&P EMED unavailable / 7.05% |
| 2016-Q30/3 |
LoseEMED / S&P EMED unavailable / 3.85% |
LoseEMED / S&P EMED unavailable / 0.20% |
LoseEMED / S&P EMED unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | EMED total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.00% | 20.78% |
| Annualized return | -50.00% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | EMED total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.78% | 83.14% |
| Annualized return | -70.60% | 12.86% |
10Y · 2019-08-14 to 2026-08-28
| Metric | EMED total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.99% | 319.30% |
| Annualized return | -61.77% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.